Remote Myocardial Ischemic Preconditioning in Humans (RemoteMIPH)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20121019031521im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.
Condition | Intervention |
---|---|
Coronary Artery Ischemia |
Device: Blood pressure cuff Device: blood pressure cuff |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
Official Title: | Remote Myocardial Ischemic Preconditioning in Humans |
- Post PCI myonecrosis measured as a maximum troponin T ≥0.03 [ Time Frame: 16 hours post PCI ] [ Designated as safety issue: No ]
- Post PCI myonecrosis measured as an elevation in creatine kinase MB fraction (CK-MB> 1 X upper limit of normal) [ Time Frame: 16 hours post procedure ] [ Designated as safety issue: No ]
- Magnitude of ST segment elevation on an intracoronary electrocardiogram during balloon inflation [ Time Frame: During PCI procedure ] [ Designated as safety issue: No ]
- Coronary perfusion measured as coronary flow reserve derived from TIMI frame counts [ Time Frame: During PCI ] [ Designated as safety issue: No ]
- Blood high sensitivity C-reactive protein level [ Time Frame: Immediately prePCI ] [ Designated as safety issue: No ]
- Blood endothelial progenitor cell counts (EPC) [ Time Frame: Immediately prePCI ] [ Designated as safety issue: No ]
Enrollment: | 156 |
Study Start Date: | October 2007 |
Study Completion Date: | June 2009 |
Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: 1
Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
|
Device: Blood pressure cuff
Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
Other Name: sphygmomanometer
|
Sham Comparator: 2
3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
|
Device: blood pressure cuff
3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
Other Name: sphygmomanometer
|
Detailed Description:
Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI. We will also test the hypotheses that IP diminishes the inflammatory response to PCI, and that higher baseline blood endothelial progenitor cell counts are predictive of a favorable response to IP.
Aim 1: To evaluate whether remote ischemic preconditioning reduces the frequency of myonecrosis (troponin T≥0.03 ng/ml following PCI).
Aim 2: To evaluate whether remote ischemic preconditioning reduces the inflammatory response to PCI (post PCI hsCRP level).
Aim 3: To evaluate whether pre-procedure circulating endothelial progenitor cell counts correlate with the effect of remote ischemic preconditioning on myonecrosis.
Background: Percutaneous coronary intervention (PCI) frequently results in ischemic myonecrosis. Ischemic preconditioning (IP) has been shown in animal studies to increase the myocardial tolerance to subsequent ischemia. Our primary hypothesis is that remote IP reduces myocardial ischemic injury during PCI.
Aims: The aims of the study are to assess in patients with coronary artery disease requiring PCI, whether remote IP reduces: 1) the frequency of myonecrosis; and 2) the inflammatory response to PCI; and 3) whether the effect of IP correlates with pre-procedure circulating endothelial progenitor cell counts.
Methods: The study is a prospective, randomized trial to assess the efficacy of remote IP as adjunctive non-pharmacological therapy for PCI in patients with stable or unstable angina. Remote IP will be performed by 3 cycles of 3-minutes of arm ischemia alternating with 3- minutes of reperfusion of the arm immediately before PCI. Myonecrosis and inflammation will be detected by measuring serum troponin T and high sensitivity C-reactive protein, respectively. Blood EPC counts will also be measured before the procedure.
![](https://webarchive.library.unt.edu/web/20121019031521im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients will be eligible for randomization if they meet the following criteria:
- Age ≥ 18 years
- Clinically indicated elective or urgent PCI
Exclusion Criteria:
Patients will be ineligible for the study if one or more of the following conditions exist:
- Pre-PCI Troponin T ≥ 0.03
- Systemic hypotension (systolic <90 mmHg) or cardiogenic shock
- Presence of an arteriovenous fistula or lymphedema of either arm
- Currently enrolled in other active cardiovascular investigational studies
- Severe endocrine, hepatic, renal, disorders
- Pregnancy or lactation
- Inability to provide consent
- Federal Medical Center inmates
- Inability or unwillingness to provide informed consent
![](https://webarchive.library.unt.edu/web/20121019031521im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
![](https://webarchive.library.unt.edu/web/20121019031521im_/http://www.clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided
Responsible Party: | Abhiram Prasad, Professor of Medicine, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00588042 History of Changes |
Other Study ID Numbers: | 06-005081, Remote MIPH |
Study First Received: | December 21, 2007 |
Last Updated: | April 18, 2012 |
Health Authority: | United States: Institutional Review Board |
Keywords provided by Mayo Clinic:
Angioplasty, Transluminal, Percutaneous Coronary Coronary Artery Disease Coronary Occlusion |
Additional relevant MeSH terms:
Ischemia Pathologic Processes |
ClinicalTrials.gov processed this record on October 17, 2012